The company's mission is to develop novel medicines for neurodegenerative diseases and neurological injuries, with a focus on relieving pain symptoms from nervous system diseases such as stroke and glaucoma. They have a strategic framework to increase success probability in CNS drug research and development, including targeting strategy, animal model development, basic-to-clinical translation, biomarkers, and clinical trial design. 4B Technologies has built a pipeline of innovative medicines through in-house drug discovery efforts and strategic alliances with academic and industrial partners. They aspire to become a global leader in developing innovative medicines for neurological diseases and began full operation in 2018 with preclinical R&D in Suzhou, and later clinical development in Beijing and Shanghai, China.